Surgery and regional-node staging review Review the recorded primary pathology, whether the definitive wide excision has been done, regional nodes and the need for a sentinel-node discussion. NCI summary for stage IA: “Excision with or without sentinel lymph node biopsy (SLNB).” | Local care Care pathway | nci-melanoma, nci-melanoma-pdq-2025 |
Post-resection surveillance discussion Plan individualized clinical, skin and regional-node follow-up; observation remains an explicit discussion. | Follow-up Care pathway | nci-melanoma |
Adjuvant pembrolizumab Discuss postoperative anti-PD-1 therapy in the supported completely resected setting. | Systemic therapy FDA-approved | keytruda-label, keynote716, kn716-final, kn054-7y |
Adjuvant nivolumab Discuss postoperative nivolumab after complete resection. | Systemic therapy FDA-approved | opdivo-label, checkmate76k, checkmate238, cm76k-primary, cm238-9y, cm238-correction |
Adjuvant dabrafenib plus trametinib Discuss adjuvant BRAF/MEK inhibition for confirmed BRAF V600E disease. | Systemic therapy FDA-approved | tafinlar-label, mekinist-spl, combiad-final |
Review discordant adjuvant BRAF V600K evidence Reconcile the broader US label with the guideline caution before any targeted adjuvant choice. | Specialist review Care pathway | tafinlar-label, combiad-final |
Neoadjuvant nivolumab plus ipilimumab, then response-guided review Discuss the NADINA strategy before surgery in macroscopic nodal stage III disease. | Systemic therapy Evidence-supported off-label | nadina, opdivo-label |
Perioperative pembrolizumab Discuss preoperative and postoperative pembrolizumab for clinically detectable, resectable disease. | Systemic therapy Evidence-supported off-label | s1801, keytruda-label |
Upfront surgery followed by adjuvant-treatment review Discuss complete local treatment followed by an explicit postoperative systemic-treatment decision. | Local care Care pathway | nci-melanoma, nadina, s1801 |
Nivolumab plus ipilimumab Discuss combined PD-1/CTLA-4 blockade in untreated advanced cutaneous melanoma. | Systemic therapy FDA-approved | opdivo-label, checkmate067-final, dreamseq, nct01844505 |
Nivolumab plus relatlimab Discuss combined PD-1/LAG-3 blockade in untreated advanced disease. | Systemic therapy FDA-approved | opdualag-label, relativity047 |
Nivolumab monotherapy Discuss single-agent PD-1 treatment. | Systemic therapy FDA-approved | opdivo-label, checkmate067-final, relativity047, nct01844505 |
Pembrolizumab monotherapy Discuss single-agent pembrolizumab. | Systemic therapy FDA-approved | keytruda-label, kn006-10y, nct01866319 |
Dabrafenib plus trametinib Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant. | Systemic therapy FDA-approved | tafinlar-label, mekinist-spl, dreamseq |
Encorafenib plus binimetinib Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant. | Systemic therapy FDA-approved | mektovi-label, braftovi-spl, mektovi-spl, columbus-7y |
Vemurafenib plus cobimetinib Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant. | Systemic therapy FDA-approved | cotellic-label, zelboraf-spl, cobrim-5y |
Nivolumab plus ipilimumab after PD-1 progression Review combined checkpoint blockade in PD-1-refractory, CTLA-4-naive disease. | Systemic therapy FDA-approved | opdivo-label, s1616 |
Lifileucel cell-therapy referral Refer a potentially appropriate previously treated patient to a specialist cell-therapy center. | Systemic therapy FDA accelerated approval | amtagvi-fda, amtagvi-review, amtagvi-label |
Talimogene laherparepvec local treatment review Discuss intralesional treatment of accessible recurrent cutaneous, subcutaneous or nodal lesions. | Local therapy FDA-approved | imlygic-label |
Multidisciplinary CNS/local-therapy review Coordinate melanoma, radiation and neurosurgical assessment, including symptoms, corticosteroid use, earlier local treatment, lesion size and whether a lesion needs immediate treatment. Lesion-directed choices named by the NCI brain-tumour summary (not specific to melanoma): “The following treatments have been used in the management of metastatic brain tumors: Radiation therapy.Radiosurgery.Surgical resection.Corticosteroids.Anticonvulsants.” For one to four metastases: “Focal therapy alone (surgical resection or stereotactic radiosurgery).” | Specialist review Care pathway | nci-cns-pdq-2025, nci-melanoma-pdq-2025 |
Sentinel-node biopsy discussion Sentinel-node biopsy discussion with the melanoma surgical team. NCI summary: “Lymphatic mapping and SLNB for patients with high-risk, thin melanomas (≥0.8 mm) or ulcerated lesions measuring less than 0.8 mm may identify individuals with occult nodal disease. These procedures should be considered, particularly if other adverse prognostic features are present.” | Local care Care pathway | nci-melanoma-pdq-2025, mslt1-final |
Sentinel-node staging review Sentinel-node biopsy discussion with the melanoma surgical team. NCI summary: “Lymphatic mapping and sentinel lymph node biopsy (SLNB) for patients who have tumors of intermediate thickness may identify individuals with occult nodal disease. Lymphatic mapping and SLNB should be considered to assess the presence of occult metastasis in the regional lymph nodes of patients with primary tumors measuring at least 0.8 mm thick with clinically negative nodes.” | Local care Care pathway | nci-melanoma-pdq-2025, mslt1-final |
Vusolimogene oderparepvec-wtpg plus nivolumab Discuss the approved intratumoral oncolytic-virus combination after progression on a PD-1-based regimen. | Systemic therapy FDA accelerated approval | tudriqev-label, tudriqev-fda |
Adjuvant nivolumab plus ipilimumab (IMMUNED schedule) A postoperative combination option for selected completely resected stage IV disease. | Systemic therapy Off-label adjuvant combination; guideline-supported discussion for selected stage IV NED patients | immuned-final, immuned-csr |
Pembrolizumab plus low-dose ipilimumab after PD-1 progression (off-label) Off-label combination studied after progression on anti-PD-1 treatment. Pembrolizumab is labelled for unresectable or metastatic melanoma; the ipilimumab label names only nivolumab as its combination partner in melanoma. | Systemic therapy Off-label combination; prospective phase II trial, 70 patients | olson-2021, nct02743819, keytruda-label, yervoy-spl |
Adjuvant pembrolizumab after complete resection of stage IV (off-label) Off-label for stage IV: “KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.” Nivolumab is the labelled adjuvant anti-PD-1 treatment for completely resected stage IV: “OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.” | Systemic therapy Off-label for stage IV; randomised phase 3 trial SWOG S1404 against interferon or ipilimumab | s1404-primary, nct02506153, keytruda-label, opdivo-label |
Imatinib for KIT-mutated acral melanoma (off-label) Off-label KIT-directed treatment studied in melanoma with a KIT mutation. Imatinib has no melanoma indication. “Melanomas that arise on mucosal, acral, or CSD skin should be assessed for KIT mutations.” | Systemic therapy Off-label; three prospective phase 2 trials (43 patients enrolled; 28 treated; 25 enrolled) | guo-2011, carvajal-2011, hodi-2013, nct00424515, gleevec-spl, nci-melanoma-pdq-2025 |
Nivolumab plus ipilimumab with active brain metastases The labelled combination for unresectable or metastatic melanoma, reviewed for active brain metastases together with the multidisciplinary CNS review. “OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.” | Systemic therapy FDA-approved indication; the label trial excluded active brain metastases (evidence limited) | opdivo-label, cm204-final, nct02320058, cm204-primary, abc-7y |
Dabrafenib plus trametinib with active brain metastases The labelled BRAF/MEK combination for BRAF V600E or V600K melanoma, reviewed for active brain metastases together with the multidisciplinary CNS review. “TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test” | Systemic therapy FDA-approved indication; the label trials excluded active brain metastases (evidence limited) | tafinlar-label, mekinist-spl, combi-mb |
Wide excision margin for the recorded thickness Definitive wide excision after the diagnostic biopsy. “A biopsy, preferably by local excision, should be performed for any suspicious lesions.” “Localized melanoma is excised with margins proportional to the microstage of the primary lesion.” A clear margin on the diagnostic biopsy is not the definitive excision margin; record which specimen the margin belongs to. | Local care Care pathway | nci-melanoma-pdq-2025 |
Tebentafusp-tebn (HLA-A*02:01-positive uveal melanoma) Bispecific gp100 peptide-HLA-directed CD3 T-cell engager indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. | bispecific_immunotherapy FDA-approved | kimmtrak-label, imcgp100-primary, imcgp100-3y |
Melphalan percutaneous hepatic perfusion (HEPZATO KIT) Liver-directed intra-arterial melphalan infusion via the HEPZATO KIT Hepatic Delivery System for adult metastatic uveal melanoma with unresectable hepatic metastases affecting <50% of the liver and absent or limited extrahepatic disease. | liver_directed_chemotherapy FDA-approved (REMS) | hepzato-label, focus-hepzato |
Nivolumab plus ipilimumab (metastatic uveal melanoma) Dual PD-1 plus CTLA-4 checkpoint blockade evaluated in two prospective single-arm phase II metastatic uveal melanoma trials (MDACC NCT01585194 and Spanish GEM-1402 NCT02626962). | checkpoint_doublet FDA-approved for unresectable or metastatic melanoma; prospective phase II uveal melanoma trials (GEM-1402, MDACC) | opdivo-label, yervoy-spl, pelster-2021, piulats-2021 |
Multidisciplinary uveal melanoma & liver-directed therapy review Specialist ocular/uveal melanoma and hepatobiliary interventional review covering HLA-A*02:01 blood genotyping, liver MRI tumour-burden assessment, regional liver-directed eligibility, and clinical trials. | care_pathway Care pathway | nci-uveal-pdq, imcgp100-primary, focus-hepzato |
Anti-PD-1-based checkpoint immunotherapy (mucosal melanoma: nivolumab plus ipilimumab or anti-PD-1 monotherapy) Systemic PD-1 blockade alone or combined with ipilimumab for unresectable or metastatic mucosal melanoma, contextualized with subtype-specific pooled prospective trial outcomes. | checkpoint_immunotherapy FDA-approved for unresectable or metastatic melanoma; mucosal melanoma pooled trial analysis | opdivo-label, yervoy-spl, keytruda-label, dangelo-2017 |
Anatomic-site surgical & radiation multidisciplinary review (mucosal melanoma) Head-and-neck, anorectal, or vulvovaginal surgical oncology, radiation oncology, and medical oncology review for mucosal melanoma staging, margin/local-control planning, and molecular profiling (KIT, BRAF, NRAS). | care_pathway Care pathway | nci-melanoma, dangelo-2017 |